key: cord-0755613-tk9r51ch
authors: Zhan, Yingzhuan; Ta, Wenjing; Tang, Wenjuan; Hua, Ruochen; Wang, Jue; Wang, Cheng; Lu, Wen
title: Potential antiviral activity of isorhamnetin against SARS‐CoV‐2 spike pseudotyped virus in vitro
date: 2021-04-13
journal: Drug Dev Res
DOI: 10.1002/ddr.21815
sha: 2d5980ab7c51564199e273efbd2bbf1db27ebf5e
doc_id: 755613
cord_uid: tk9r51ch

Coronavirus Disease 2019 (COVID‐19) cases and deaths are still rising worldwide, there is currently no effective treatment for severe inflammation and acute lung injury caused by new coronavirus (SARS‐COV‐2) infection. Therapies to prevent or treat COVID‐19, including antiviral drug and several vaccines, are still being development. Human angiotensin‐converting enzyme 2 (ACE2), expressing in lung, has been confirmed to be a receptor for SARS‐COV‐2 infection, interventions for attachment of spike protein of SARS‐CoV‐2 to ACE2 may be a potential approach to prevent viral infections and it is considered as a potential target for drug development. In this study, we observed that seabuckthorn and its flavonoid compounds quercetin and isorhamnetin were shown strong retention to ACE2 overexpression HEK293 (ACE2(h)) cells by CMC analysis. Based on drug receptor interaction analysis and viral entry studies in vitro, we evaluated the interaction of two flavonoid compounds and ACE2 as well as the inhibitory effect of the two compounds on viral entry. Surface plasmon resonance assay proved the effect that isorhamnetin bound to the ACE2, and its affinity (KD value) was at the micromolar level, that was, 2.51 ± 0.68 μM. Viral entry studies in vitro indicated that isorhamnetin inhibited SARS‐CoV‐2 spike pseudotyped virus entering ACE2(h) cells. Based on promising in vitro results, we proposed isorhamnetin to be a potential therapeutic candidate compound against COVID‐19.

The disease caused by SARS-CoV-2 virus infection has been named Coronavirus Disease 2019 . Its pandemic is one of the most serious global public health crises to date. It produces clinical symptoms that include fever, dry cough, dyspnea, headache, pneumonia with potentially progressive respiratory failure owing to alveolar damage, and even death (Nishiga et al., 2020; Patel et al., 2020; Scimeca et al., 2020) .

Currently, at the end of 2020, the death toll from the COVID-19 pandemic worldwide reached 1.6 million, as the total number of infections exceeded 72 million. The treatment options for COVID-19 are very limited, and several vaccines can be prevented SARS-CoV-2 virus is under development (Flanagan et al., 2020; Jeyanathan et al., 2020; Tregoning et al., 2020) . Drug repurposing has been used to deal with emerging infectious diseases so as to quickly discover potential treatments. Unfortunately, remdesivir, an Ebola virus (EBOV) inhibitor, that were once considered the most promising therapeutic drug has also been confirmed to be ineffective in clinical studies (Pruijssers et al., 2020; Spinner et al., 2020; . To date, there is no effective prevention and treatment strategy for this disease, the main treatment strategy is limited to symptomatic treatment and organ support for patients with COVID-19 and severe or critical illness, such as corticosteroid therapy and antiviral therapy, oxygen therapy (Zumla et al., 2020) .

The therapeutic target of COVID-19 can be directed against the SARS-CoV-2 virus and its protein or host cell targets. Angiotensinconverting enzyme 2 (ACE2), an important metalloprotease, is a negative regulator of the renin-angiotensin system, which balances the function of ACE to maintain blood pressure homeostasis (South et al., 2020) . Evidence shows that ACE2 is expressed in tissues such as heart, lung, kidney, liver, intestine, and testis (Imai et al., 2010; Tipnis et al., 2000) , and it has been confirmed to mediate COVID-19 virus infection (Bourgonje et al., 2020; Devaux et al., 2020) . It is known that one approach of SARS-CoV2 entering the recipient host cell is interaction with angiotensin-converting enzyme (ACE) 2 on the cell membrane of pulmonary epithelial cells Lu et al., 2020; Walls et al., 2020) . Structural analysis shows that the spike protein of SARS-CoV-2 attaches to ACE2 by contacting the apex of subunit I of the ACE2 catalytic domain . Once attached by SARS-CoV-2, the ectodomain of ACE2 will be cleaved and the transmembrane region or whole molecule of ACE2 along with the virus enters the cell by endocytosis (Wrapp et al., 2020) . Therefore, interventions for ACE2 have aroused great interest in reducing viral infections. Interruption of interaction between spike protein and ACE2, thereby preventing SARS-CoV-2 receptor binding and subsequent spread of infection might be a potential approach to treat COVID-19 patients (Barlow et al., 2020; Wu et al., 2020) .

Previous studies reported that plant secondary metabolites are helping to prevent viral infection, such as sea-buckthorn, green tea, honeysuckle, and so forth (Choi et al., 2012; Enkhtaivan et al., 2017; Patil et al., 2013) . Seabuckthorn, also called Hippophae rhamnoides L., belonging to the family of Elaeagnaceae, is a berries plant native to the Asian and Europe.

Berries of Seabuckthorn were used as traditional medicine in Asia (Bal et al., 2011; Enkhtaivan et al., 2017) . Seabuckthorn berries contain lots of chemical compounds, nearly 200 bioactive ingredients have been found in seabuckthorn fruits, including flavonoids (isorhamnetin, quercetin, kaempferol, etc.) , phenolic acid (gallic acid, vanillic acid, P-coumaric acid, etc.), vitamin C, vitamin E, carotenoids, amino acids and minerals (iron, calcium, phosphorus and potassium), and so forth (Kwon et al., 2017; Olas, 2016) . Sea buckthorn berries extract is proved to have the activities of antioxidant, antiviral, anticancer, blood glucose and blood lipids regulation, immune regulation and anti-inflammation Enkhtaivan et al., 2017; Larmo et al., 2013; Olas et al., 2018; Xing et al., 2002) . In this study, we investigated the antiviral activity of active products of sea buckthorn berries against SARS-CoV-2 spike pseudotyped virus in vitro and found that isorhamnetin antagonized ACE2 and blocked the entry of 2019-nCoV spike pseudotyped virus into ACE2 h cells. Some literatures reported flavanols including isorhamnetin and quercetin are considered as potential antiviral drugs targeting SARS-CoV-2 proteases, spike protein, RNA-dependent RNA polymerase (RdRp) or ACE2 receptor. However, these studies predicted targets of these compounds based on computer-based analysis, such as network pharmacological study , virtual screening or molecular docking (Derosa et al., 2020) . Our studies investigated and confirmed experimentally the antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus, which might provide a new preliminary leading compound to be develop as therapeutics against COVID-19. 

The ACE2 h cell line was constructed by Genomeditech (Shanghai, China). ACE2 h cells were maintained in DMEM high glucose medium, which contained 10% (vol/vol) fetal bovine serum (FBS), 1% penicillin-streptomycin and 4 μg/ml puromycin. All cell lines were cultured in a 5% CO 2 incubator at 37 C.

The berries of Sea-buckthorn were commercially available as dry matter. The raw material was crushed and refluxed gently in 10 volumes of 95% ethanol (vol/wt) for 1 h for two times. The merged extracting solutions were filtered, and supernatant was evaporated under reduced pressure and dried in vacuum conditions overnight. The dry powder was stored at 4 C and dissolved in methanol before use.

The stock solutions of sea-buckthorn extract (SBE, 25 mg/ml), isorhamnetin (1 mg/ml) and quercetin (1 mg/ml) were prepared by separately dissolving the extract dry powder or the standard compounds in methanol. All chromatographic experiments were conducted at 37 C and PBS was used as the mobile phase.

ACE2 h cells (1 × 10 7 ) were harvested and washed three times with 5 mM PBS by centrifuging at 3000×g for 10 min, and the pellet was re-suspended with 50 mM Tris-HCl (pH 7.4), followed by ultrasonic destruction for 30 min. The homogenate was centrifuged at 1000×g for 10 min, and supernatant was collected and centrifuged at 12,000×g for 10 min. The precipitate was then suspended with 5 mM PBS. ACE2 h CMSP was prepared by adsorption of the cell membrane suspension (5 ml) on the activated silica (0.05 g) under vacuum and with a gentle agitation. The CMSP was placed overnight and then washed five times with 5 mM PBS. Finally, the mixture obtained was packed into a column (10 × 2.0 mm I.D.) using a wet packing method (5 MPa, 20 min). All the procedure was performed at 4 C.

CMC analysis was performed on a Shimadzu LC-2040C apparatus (Shimadzu, Kyoto, Japan), and the data acquired by the LCsolution software (Shimadzu, Kyoto, Japan) was processed by Graph-Pad Prism version 6.0 (San Diego, CA, USA). The detection wavelengths were 205 nm for SBE, 292 nm for isorhamnetin, 273 nm for quercetin. The chromatographic conditions were as follows: flow rate, 0.2 ml/min; column temperature, 37 C; mobile phase, ultrapure water.

Cell viability was determined by CCK8 kit following the manufacturer's instructions. First, exponentially growing ACE2 h cells were collected and seeded into 96-well plates at a density of 5 × 10 3 cells/well, and then the cells were treated with different concentrations of drugs (0, 0.1, 1, 10, 50, 100, 200, 300 and 400 μM) for 24 h, then CCK8 solution were added to each well and incubated at 37 C for 2 h. the absorbance at 450 nm was measured with a microplate reader (Bio-Rad, Carlsbad, California) to evaluate the relative cell viability. The formula for calculating the survival rate of ACE2 h cells is as follows: Then cells were washed three times with CIB and used immediately for imaging. Cells loaded Fluo-3 were observed at 488 nm excitation.

Ten seconds after imaging starts, compounds were added to the wells and responses were monitored at 1 s intervals for an additional 120 s.

For assessment of interactions of small molecules and ACE2 protein, surface plasmon resonance (SPR) was adopted in this experiment. ACE2 protein with a 6-his tag (30 μg/ml) was covalently 

Spike pseudotyped virus entry assay was conducted as described previously . ACE2 h cells at the density of 5 × 10 4 in 50 μl medium per well were seeded into 96-well plates and cultured in 37 C for 2 h. After adherent, 25 μl of medium per well was discarded carefully, and same volume medium containing the tested drugs was added into plate for 2 h treatment. Subsequently, 5 μl of SARS-CoV-2 spike pseudotyped virus was added the plate and incubated at 37 C for 4 h, then 100 μl of complemented DMEM per well was added for 2 h incubation. Two hundred microliters per well of fresh DMEM medium was added to replace the culture medium containing the virus and incubated continuously at 37 C for 48 h. Twenty microliters of cell lysate was measured by the Luciferase Assay System (Promega, E1500), chemiluminescence was detected at 560 nm with a 1 s exposure time using a microplate reader.

Molecular docking assays were carried out using SYBYL-X 2.0 version. The small molecules and X-ray crystal structure of the protein (PDB code: 6M0J) were imported. Water molecules were removed and hydrogen was added. Tripos force field and Pullman charge were applied to minimize. Isorhamnetin were depicted by the Sybyl/ Sketch module (Tripos Inc.), optimized by Powell's method with the Tripos force field with convergence criterion at 0.005 kcal/(Å mol), and assigned using Gasteiger-Hückel method.

Data were shown as the mean ± SEM, and statistical analysis was performed by analysis of variance, two-tailed test was used for comparison between the two groups. The difference was statistically significant at p < .05.

The ACE2 h /CMC column was used to identify the active compound in SBE which could target ACE2. We found that SBE showed retention on the ACE2 h /CMC column, and retention time was 28.4 min 

To measure the direct binding of quercetin and isorhamnetin to the ACE2, the equilibrium dissociation constant (KD) of quercetin and isorhamnetin binding to ACE2 was performed with SPR technology.

Increasing concentrations of compounds were injected on sensor chips with immobilized recombinant ACE2. As shown in Figure 2 , quercetin bound to ACE2 protein with an KD (5.92 ± 0.92) μM, and isorhamnetin with an KD (2.51 ± 0.68) μM. That was, both quercetin and isorhamnetin showed affinity to ACE2 recombinant protein on SPR chips.

The toxicity of quercetin and isorhamnetin on ACE2 h cells were assessed by the change in cell viability and intracellular Ca 2+ flux.

CCK8 assay was used to evaluate the effect of quercetin and isorhamnetin on cell viability. As shown in Figure 3a (Figure 3c,d) .

We 

Literature studies have shown that the RBD binding domain of spike protein can bind to ACE2 at R393, R357, K353, Y83, Q42, Y41, D38, E37, E35, H34, K31, D30, and Q24 locations (Lan et al., 2020; Yan et al., 2020) , thereby infecting cells, causing toxicity.

Molecular docking was carried out to identify the critically binding regions of the isorhamnetin with ACE2. As shown in Figure 5 , isorhamnetin bound with K353, E37, and H34 on ACE2. It was obvious that isorhamnetin shared three amine acids of ACE2 with SARS-CoV-2.

Developing the antiviral therapy drug is an urgent need to suppress the a common TCM, was found to possess a very strong antiviral activity and wide range of action against avian influenza and herpes viruses (Enkhtaivan et al., 2017) . In this study, we found that SBE exhibited strong interaction with ACE2 by using CMC analysis. Isorhamnetin and quercetin are the major compounds of flavonoid derived from Sea buckthorn berries, and they are proved to inhibit atherosclerotic plaque development, protect against cardiac hypertrophy, inhibit the production of reactive oxygen species, and exert antioxidant properties in vitro (Luo et al., 2015) . Thus, we speculated quercetin and isorhamnetin might be the compounds binding to ACE2, so we further explored their interactions with ACE2, as well as their ability to prevent viral entry, thus might exerted potential antiviral in vitro.

ACE2 is proved to be the receptor for SARS-CoV-2, theoretically, all organs with high expression of ACE2 are susceptible to SARS-CoV-2

infection. SPR analysis proved the two compounds could bind to ACE2

with the affinity at micromolar. The entry of viruses into host cells is a crucial step in the process of viral infection, blocking the entry process of the virus was considered to be the way to prevent infection. To further evaluate the effect of quercetin and isorhamnetin on viral entry, ACE2 overexpression HEK293 cells was constructed and used for in vitro screening and characterization of quercetin and isorhamnetin against SARS-CoV-2 in this study. Experiment studies performed on highly pathogenic viruses like the novel SARS-CoV-2 virus must be carried out in laboratories that satisfy strict biosafety level (BSL) requirements. Unfortunately, the requirements of high BSL, such as BSL-3 and BSL-4 labs often prevent more than a few specific institutions from handling these researches. The pseudovirus system is a useful alternative approach that can effectively screen drugs on pathogenic viruses outside of a BSL-3 or BSL-4 level laboratory . The SARS-CoV-2 pseudovirus was able to simulate the process of the virus entering the cells and then infect cells, so it was used for this study to 

Sea buckthorn berries: A potential source of valuable nutrients for nutraceuticals and cosmeceuticals

Review of emerging pharmacotherapy for the treatment of coronavirus disease

Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

Sea buckthorn (Hippophae rhamnoides L.) leaf extracts protect neuronal PC-12 cells from oxidative stress

Quercetin 3-rhamnoside exerts antiinfluenza A virus activity in mice

A role for quercetin in coronavirus disease 2019 (COVID-19)

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

Extreme effects of Seabuckthorn extracts on influenza viruses and human cancer cells and correlation between flavonol glycosides and biological activities of extracts

Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines

Possible transmission flow of SARS-CoV-2 based on ACE2 features

Review on the potential action mechanisms of Chinese medicines in treating coronavirus disease 2019 (COVID-19)

Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis

Immunological considerations for COVID-19 vaccine strategies

Seabuckthorn leaves extract and flavonoid glycosides extract from seabuckthorn leaves ameliorates adiposity, hepatic steatosis, insulin resistance, and inflammation in diet-induced obesity

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Effects of sea buckthorn and bilberry on serum metabolites differ according to baseline metabolic profiles in overweight women: A randomized crossover trial

Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding

Isorhamnetin attenuates atherosclerosis by inhibiting macrophage apoptosis via PI3K/AKT activation and HO-1 induction

COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives

The anticancer activity of sea buckthorn [Elaeagnus rhamnoides

Sea buckthorn as a source of important bioactive compounds in cardiovascular diseases

Coronavirus (SARS-CoV-2) in the environment: Occurrence, persistence, analysis in aquatic systems and possible management

Evaluation of Jatropha curcas Linn. leaf extracts for its cytotoxicity and potential to inhibit hemagglutinin protein of influenza virus

Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice

Imaging diagnostics and pathology in SARS-CoV-2-related diseases

The structural basis of accelerated host cell entry by SARS-CoV-2

Cell entry mechanisms of SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

COVID-19, ACE2, and the cardiovascular consequences

Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Vaccines for COVID-19

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV spike pseudotyped virus

Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Effects of sea buckthorn (Hippophaë rhamnoides L.) seed and pulp oils on experimental models of gastric ulcer in rats

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro

Reducing mortality from 2019-nCoV: Host-directed therapies should be an option

Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro

The authors declare no competing financial interest.

The contents of the manuscript are shared upon request.

https://orcid.org/0000-0001-8728-7099